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Optimising response to tyrosinekinase inhibitors in cancer remains
an extensive field of research. Intravital
imaging is an emerging tool, which can
be used in drug discovery to facilitate and
fine-tune maximum drug response in live
tumors. A greater understanding of intra-
tumoural delivery and pharmacodynam-
ics of a drug can be obtained by imaging
drug target-specific fluorescence reso-
nance energy transfer (FRET) biosensors
in real time. Here, we outline our recent
work using a Src-FRET biosensor as a
readout of Src activity to gauge optimal
tyrosine kinase inhibition in response to
dasatinib treatment regimens in vivo. By
simultaneously monitoring both the
inhibition of Src using FRET imaging,
and the modulation of the surrounding
extracellular matrix using second har-
monic generation (SHG) imaging, we
were able to show enhanced drug pene-
trance and delivery to live pancreatic
tumors. We discuss the implications of
this dual intravital imaging approach in
the context of altered tumor-stromal
interactions, while summarising how this
approach could be applied to assess other
combination strategies or tyrosine kinase
inhibitors in a preclinical setting.
Introduction
Optimal drug delivery into solid
tumors can be impaired by several fac-
tors1,2 Deregulation of the extracellular
matrix (ECM) composition of the tumor
microenvironment is a major determinant
controlling drug penetrance. The
increased deposition of ECM and subse-
quent fibrosis in pancreatic ductal
adenocarinoma (PDAC) can limit drug
perfusion into the tumor mass.3 This pro-
cess in pancreatic cancer is governed by
tumor-associated stellate cells, which pro-
duce excessive amounts of collagen type I
and other ECM components, such as
fibronectins, leading to restricted drug
delivery within the tissue.4,5 Due to its
fibrillar structure collagen type I can be
visualized using multi-photon intravital
microscopy. Its compact molecular struc-
ture generates a second harmonic genera-
tion (SHG) signal when excited with high
energy pulsed laser.6 This signal can then
be further quantified7 and the manipula-
tion and efficacy of anti-ECM treatment
regimens can be evaluated by live intravi-
tal imaging.8
Recently, we demonstrated a correla-
tion between Src expression levels and
reduced survival in human pancreatic
cancer, and showed that the activity of
Src is an indicator of invasion and poor
prognosis in human pancreatic cancer
patients.9 Importantly, we also estab-
lished that the phase II, small molecule
Src inhibitor, dasatinib, which is cur-
rently being clinically evaluated in com-
bination with chemotherapy in locally
advanced PDAC,10 inhibited invasion of
primary PDAC cells generated from the
KrasG12D/C, Trp53R172H/C, Pdx1-Cre
(KPC) model of pancreatic cancer, and
reduced the development of metastases
by approximately 50%.11-13 In order to
visualize Src activity upon treatment and
inhibition with dasatinib within single
cancer cells, we employed a FRET-based
Src reporter in cells generated from this
model to map the pharmacodynamics of
the Src inhibitor dasatinib in vivo
(Fig. 1).8,9,12,14
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The Src reporter consists of an SH2
domain, a flexible linker and a peptide
sequence derived from the c-Src substrate
p130cas, flanked by 2 spectrally overlap-
ping fluorophores ECFP and YPet.14
When the substrate of Src kinase is
unphosphorylated, the fluorophores
remain in close proximity, leading to high
FRET efficiency. Upon Src-induced phos-
phorylation, the substrate peptide binds to
the SH2 domain and separates YPet from
ECFP, thereby decreasing FRET effi-
ciency (Fig. 1A). This can be quantified
by measuring the fluorescent lifetime
(FLIM) of ECFP, which decreases when
the reporter assumes a FRET-conforma-
tion. FLIM-FRET signals are then repre-
sented in heat-maps, where red to yellow
colors are attributed to Src activity and
blue to green colors represent inactive Src
(Fig. 1B and C).
This application of live functional
imaging of Src activity with the use of
FLIM-FRET allowed us to gauge Src
activity and drug treatment response with
high spatiotemporal resolution in a com-
plex setting. We assessed the temporal
inactivation of Src in response to dasatinib
in live tumor tissue and were able to
observe and quantify a drug clearance rate
post oral administration (Fig. 2A). Src
was inactive at 2 hours post-dasatinib
treatment and a gradual reactivation was
observed after 4–6 hours, peaking and
overcompensating at 16 hours before
returning to control levels after 24 hours.
We then assessed spatial regulation by
examining Src activity in distinct locations
within a complex microenvironment.
Three-dimensional organotypic assays
showed increased Src activity in propor-
tion to PDAC invasive status
(Fig. 2B,8,15). Similarly, this gradient also
exists within live tumors, where Src activ-
ity is enhanced at invasive borders, relative
to the tumor center, correlating with
metastasis in this model.8,9 Importantly,
the organization and deposition of ECM
components correlated with Src activity in
vivo, where a highly organized, dense
ECM was associated with high Src activity
(quantified by SHG imaging and Gray
Level Co-occurrence Matrix (GLCM)
analysis, as previously described7,8,16).
Further analysis revealed that Src regula-
tion in response to dasatinib was also gov-
erned by the proximity of cells to the host
vasculature (shown using quantum dots
(Fig. 3A, red)). Cells distal to the vascula-
ture (>100 mm) were less responsive to
dasatinib treatment than those close to
blood vessels (Fig. 3B, <25 mm). This
detailed spatiotemporal mapping of drug
performance in the context of vascularisa-
tion in vivo, combined with the capacity
to simultaneously track ECM integrity,
allowed us to utilize this technology to
monitor improvements in dasatinib
delivery at a subcellular resolution in
response to ECM-targeted therapy.8
Targeting the ECM architecture to
enhance drug penetration has recently
been employed to improve chemothera-
peutic drug delivery in solid tumor types
such as pancreatic cancer. In particular,
the role that stromal tissue plays in the
perfusion deficit found in pancreatic can-
cer has been a rapidly evolving area of
research.17-19 In the KPC pancreatic
mouse model described here, treatment
with the hedgehog signaling inhibitor,
IP-926, to deplete the tumor-associated
ECM, increased tumor perfusion and the
therapeutic index of standard-of-care che-
motherapeutic agents such as gemcitabine
resulting in increased overall survival.19
Similarly, the enzymatic depletion of
ECM glycosaminoglycans has recently
been shown to improve the intratumoural
delivery and efficacy of gemcitabine
in vivo.17,18 These studies therefore sug-
gested that the current failure of drugs in
the treatment of solid tumors may arise,
partly, from a potentially reversible
impairment in intratumoural drug deliv-
ery. We therefore determined whether a
similar strategy could be adopted for dasa-
tinib treatment in vivo.9,10
In order to make the inherently dense
tumor mass more accessible to dasatinib
treatment, tumors were pre-treated with
the hedgehog signaling inhibitor,
Figure 1. FRET-based Src biosensor in vivo. (A) Functional schematic of the Src biosensor in both a FRET (bottom) and non-FRET conﬁrmation (top). The
probe is phosphorylated by active Src and dephosphorylated by phosphatases within the cell. The activity of Src is represented by the FLIM-bar, denot-
ing Src-active (red to yellow) and -inactive colors (green to blue). (B and C) Src activity distribution in single cells at subcellular resolution in relation to
local vasculature in vivo, with vasculature in red (quantum dots, Qtracker655), collagen in magenta (detected by SHG imaging) and cells in the FLIM col-
ors; Scale bars in (B and C), 50 mm.
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cyclopamine, to reduce ECM con-
tent.19,20 Manipulation of the surround-
ing ECM levels with cyclopamine and
maintenance of tissue integrity was moni-
tored by SHG imaging in conjunction
with simultaneous FLIM-FRET imaging
of the Src reporter.8 A significant
improvement in Src inhibition was
achieved throughout the tumor mass
using this approach, both at the tumor
border versus the center, and at sites dis-
tant from the vasculature. Interestingly, at
>100 mm from the vasculature, a limit
was reached whereby no further inactiva-
tion of Src could be achieved. This could
potentially be due to the limit of perfusion
within the tissue or could be due to hyp-
oxic and metabolic changes in tumor cells
Figure 2. Monitoring targeted response to dasatinib in vivo and in vitro using FLIM-FRET. (A) Drug treatment regimen and imaging schedule (top) allow-
ing for monitoring of dasatinib treatment efﬁcacy in vivo over time, with collagen in magenta (detected by SHG imaging) and cells in green (middle)
with corresponding lifetime maps of Src activity (bottom). (B) Src activity distribution in single cells in relation to penetration depth through collagen
matrix in vitro, assessed by immunohistochemistry for phosphorylated Src (left, pSrc positive cells stain brown) or by FLIM-FRET with corresponding
quantiﬁcation at 20 mm resolution steps (right). Columns, mean; bars, standard errors; *, p D 0.027; **, p D 0.021; ***, p D 0.006; ****, p < 0.001 by
unpaired Student t test. Figure, partially reproduced from original highlighted paper (8 courtesy of Cancer Research).
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distant from the vasculature preventing
dasatinib efficacy in this subpopulation.
Further studies to assess whether this is
the case are currently being carried out.
The concept that the ECM acts as a
barrier to dasatinib diffusion within the
tumor is unlikely to be the only explana-
tion for the improved dasatinib response
we observe in combination with ECM-
targeted therapy. In Fig. 4, we propose
that in cases of high fibrosis there is a bi-
directional positive feedback loop between
tumor cells and the surrounding ECM
inducing Src signaling via integrin engage-
ment, increasing the robustness of Src
activity.21,22 Upon ECM depletion or
relaxation, this feedback may be reduced,
thereby indirectly priming Src activity
within the tumor to be more receptive to
dasatinib treatment in combination ther-
apy. In accordance with this, direct treat-
ment of PDAC cells in vitro, with
cyclopamine alone, had no effect on Src
activity, while in the presence of signaling
from the surrounding matrix in vivo,
cyclopamine priming enhanced Src inacti-
vation in response to dasatinib. Current
studies to determine the level to which
indirect ECM signaling or malperfusion
plays a role in this dual targeting approach
are underway.23,24
In this work we used a single time
point to observe improved spatial inactiva-
tion of Src with combination therapy. It
would be interesting for future studies to
determine whether, upon ECM priming,
the timing of Src inactivation occurs more
rapidly or whether dasatinib accumulates
and resides in the tumor for different time
periods due to reduced matrix levels.
Monitoring the relationships between spa-
tial coverage and timing of drug delivery
and drug retention is difficult, and this
must be taken into consideration when
streamlining improved drug targeting in
future studies.25
Targeting Other Aspects of the
Tumor Microenvironment
In addition to the abundance of ECM
components, tumors are heterogeneous
tissues containing other elements such as
blood vessels, lymphatic tissue and tumor-
associated cell types such as fibroblasts,
pericytes and immune cells.26-31 The
tumor microenvironment can therefore
supply cancer cells with important cues
during tumor progression and as is the
case for the ECM, other aspects of the
tumor environment could be important
drug targets.
Blood vessels as transporters of oxygen,
nutrients and therapeutic drugs are com-
monly deregulated in tumors. Their
Figure 3. Shifting of spatial distribution of Src activity distant from local vasculature after drug treatment, as revealed by intravital imaging. (A) Innate
gradient of Src activity distant from tumor vasculature, visualized by FLIM-FRET in conjunction with the quantum dot signal. (B) Quantiﬁcation of shift in
distribution of Src activity in single cells in relation to vessel proximity after dasatinib treatment (C) or after dasatinib treatment in combination with an
ECM inhibitor (cyclopamine). Columns, mean; bars, standard errors. Figure, rearranged and reproduced from original highlighted paper (8 courtesy of
Cancer Research).
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architecture is often poorly organized,
leading to irregular blood flow, and due to
the highly proliferative nature of tumor
cells, blood and lymphatic vessels can
become compressed within many solid
tumors. As a result, this disordered com-
position of the vascular system often hin-
ders drug penetrance in solid tumor types
such as pancreatic cancer.1,17,18 In line
with this, recent work has demonstrated
that ECM depletion reverts this compres-
sion and improves vascularity indi-
rectly.17,18 Another approach to enhance
treatment efficacy could therefore be the
indirect remodelling of the tumor vascula-
ture. This has recently been shown with
angiotensin inhibition and the associated
downstream decrease in expression of pro-
fibrotic signals such as transforming
growth factor (TGF)-b1, connective tissue
growth factor (CTGF) and endothelin
(ET)-1.32 Here, the authors show that
stress exerted upon vessels by excessive
deposition of collagen and ECM compo-
nents in breast and pancreatic tumors was
decreased by angiotensin inhibition using
losartan, and thus vascular perfusion and
chemotherapeutic drug delivery was
increased.32 Repurposing of angiotensin
inhibitors or similar drugs in this way
could therefore be used in future combi-
nation treatments to improve drug pene-
trance. Similarly, actively increasing
vascular patency directly could also help
anti-cancer agents enter the tumor tissue
more readily (Fig. 4). To achieve higher
penetration of anti-cancer agents, drugs
such as fasudil33,34 or ascorbate35 could be
used, which have been shown previously
to directly increase the patency of vessels.
Monitoring and maximizing these direct
or indirect improvements of drug
targeting combinations by FLIM-FRET
analysis may be used in future preclinical
settings to fine-tune such drug targeting
combinations.8,36,37
Conversely, many tumor types are
often associated with poor vasculature
and vascular leakage, which impairs the
efficiency of intratumoural blood pres-
sure to drive effective drug delivery to
the entire tumor. Targeting the vascula-
ture using anti-angiogenics could help
to improve drug delivery and retention
in this scenario by normalization of the
vessels, leading to a reduced number of
leaky vessels and improving the intratu-
moural blood pressure of the existing
vasculature (Fig. 5). Recently, the
VEGF receptor tyrosine kinase inhibitor
axitinib allowed for a longer retention
time of an anti-cancer pro-drug within
tumors to improve cyclophosphamide
Figure 4. Improving drug distribution away from the vasculature by targeting the ECM and decreasing its deposition, leading to a reduction in ECM
exerted force and decreased integrin engagement and thus potentially a decrease / a longer suppression of Src activity.
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cytotoxic activity in gliosarcoma xeno-
grafts.38 This blood vessel stabilization
approach has also previously been
observed for the treatment of tumors
with the anti-angiogenic antibodies
DC101 or bevacizumab as monothera-
pies.39,40 These effects, however, were
only transiently obtained and thus a
careful scheduling of pre-treatment of
tumors with anti-angiogenics in combi-
nation with other anti-cancer agents is
key for their potential future clinical
success. In order to optimally induce
the normalization of the vasculature at
the right time of treatment and thus
maximise the retention of the drug in
question, we propose that live intravital
imaging of target inactivation could be
employed in conjunction with monitor-
ing blood vessel changes and
permeability using quantum dots or
fluorescent dextrans, as recently
achieved.8,37,41-43
Our application of matching the drug
of choice with available target reporters
opens up new possibilities for precise
monitoring of spatiotemporal signaling
in drug discovery. Here, we matched
dasatinib treatment with a Src-FRET
reporter in a model of invasive pancre-
atic cancer in which Src inhibition has
previously shown promise in both ani-
mal models and current phase II clinical
trials.9,10 However, FRET reporters of
different targets in other models of dis-
ease or drug treatments could also be
applied in a comparable fashion (Fig. 6,
drug A matched with target A). Simi-
larly, indirect readout of downstream
targets could also be achieved using this
setup (Fig. 6, drug B). For example, Src
activity downstream of EGFR targeting
via gefitinib could be assessed in the cur-
rent setup and may provide additional
detail to the signal transduction cascade
in receptor tyrosine kinase (RTK)-driven
disease states in response to drug treat-
ment.44,45 Expression of multiple FRET
biosensors within the same cell, which
do not spectrally overlap, are also
becoming available and could provide
distinct parallel or antagonistic informa-
tion in response to single agent treat-
ments (Fig. 6, drug C,46-49). This
spatiotemporal approach could also be
used to monitor signaling feedback loops
to dissect redundant or resistance mech-
anisms in response to drug treatment
(Fig. 6, drug C,50). Moreover, targeting
of stromal cell types, such as fibroblasts
or immune cell populations within
tumors, could also be assessed for para-
crine interactions with cancer cells and
indirect targets could be monitored with
fine temporal and spatial resolution
using this approach (Fig. 6, drug D).
Furthermore, this application in subcu-
taneous xenograft tumors lacks the inher-
ent host environment unique to the tissue
type in question. Our latest genetic engi-
neering of a FRET reporter mouse,51
crossed to pancreatic, mammary and
intestinal tumor models has recently
allowed us to apply this approach to native
tissue and could provide significant insight
into how molecular targets commonly
hijacked in cancer behave in more physio-
logical and functional settings in the
future.51 Finally, the use of cutaneous or
abdominal optical windows52–54 permits
longitudinal monitoring of protein activ-
ity in vivo in the same animal over
repeated imaging periods and may further
advance the screening of drug targeting
efficacy in this setting.
In conclusion, the capacity to monitor
changes in drug targeting at the molecular
level in the context of the tumor land-
scape, including the proximity of cells to
the host vasculature, their location with
regards to tumor invasive borders and the
integrity of the surrounding ECM or
blood supply, could provide unprece-
dented insight into how best to streamline
drug targeting within live tumor
environments.
Figure 5. Targeting the tumor vasculature to increase drug treatment efﬁcacies. (A) Application
of a potential anti-angiogenic leading to vessel normalization prior to treatment with the Src
inhibitor could lead to an increase of drug retention time within the tumor mass. (B) An increase
in vascular patency could lead to an increase in the potential inﬂux of the Src inhibitor.
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